Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia

Critical Care Medicine

Volumn 35, Issue 8, 2007, Pages 1966-1971

  Gierer, Philip ^a   Hoffmann, Johannes N ^b   Mahr, Felix ^a   Menger, Michael D ^c   Mittlmeier, Thomas ^a   Gradl, Georg ^a   Vollmar, Brigitte ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Coagulation; Lipopolysaccharide; Microcirculation

Indexed keywords

ACTIVATED PROTEIN C; BACTERIUM LIPOPOLYSACCHARIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CELL INTERACTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTOXEMIA; ESCHERICHIA COLI; EXTENSOR DIGITORUM LONGUS MUSCLE; FLUORESCENCE MICROSCOPY; HYPOXEMIA; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; MALE; MICROSURGERY; MUSCLE CELL; MUSCLE INJURY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; SKELETAL MUSCLE; SOFT TISSUE INJURY; TISSUE OXYGENATION; TISSUE PERFUSION;

ANALYSIS OF VARIANCE; ANIMALS; ANTICOAGULANTS; APOPTOSIS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICROCIRCULATION; MULTIPLE ORGAN FAILURE; MUSCLE, SKELETAL; PROTEIN C; RATS; RATS, SPRAGUE-DAWLEY; SOFT TISSUE INJURIES;

EID: 34547662013     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000275270.14835.2A     Document Type: Article

References (31)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Hoffmann JN, Fertmann JM, Jauch K: Microcirculatory disorders in sepsis and transplantation: Therapy with natural coagulatory inhibitors antithrombin and activated protein C. Curr Opin Crit Care 2006; 12:426-430
3. McCuskey RS, Urbaschek R, Urbaschek B: The microcirculation during endotoxemia. Cardiovasc Res 1996; 32:752-763
4. Bernard GR: Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31:S85-S93
5. Bernard GR, Vincent JL, Laterre PF, et al: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
6. Warren BL, Eid A, Singer P, et al: KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
7. Barie PS, Williams MD, McCollam JS, et al: PROWESS Surgical Evaluation Committee. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004; 188:212-220
8. Wiedermann CJ, Kaneider NC: A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med 2005; 5:7
9. Abraham E, Laterre PF, Garg R, et al: Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
10. Hoffmann JN, Vollmar B, Laschke MW, et al: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004; 32:1011-1017
11. Iba T, Kidokoro A, Fukunaga M, et al: Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33:368-372
12. De Backer D, Verdant C, Chierego M, et al: Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 2006; 34:1918-1924
13. Schaser KD, Vollmar B, Menger MD, et al: In vivo analysis of microcirculation following closed soft-tissue injury. J Orthop Res 1999; 17:678-685
14. Mittlmeier T, Vollmar B, Menger MD, et al: Small volume hypertonic hydroxyethyl starch reduces acute microvascular dysfunction after closed soft-tissue trauma. J Bone Joint Surg Br 2003; 85:126-132
15. Gierer P, Mittlmeier T, Bordel R, et al: Selective cyclooxygenase-2 inhibition reverses microcirculatory and inflammatory sequelae of closed soft-tissue trauma in an animal model. J Bone Joint Surg Am 2005; 87:153-160
16. Dixon CE, Clifton GL, Lighthall JW, et al: A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Methods 1991; 39:253-262
17. Lighthall JW, Dixon CE, Anderson TE: Experimental models of brain injury. J Neurotrauma 1989; 6:83-97
18. Tyml K, Budreau C: A new preparation of the rat extensor digitorum longus muscle for intravital investigation of the microcirculation. Int J Microcirc Clin Exp 1991; 10:335-343
19. Vollmar B, Burkhardt M, Minor T, et al: High-resolution microscopic determination of hepatic NADH fluorescence for in vivo monitoring of tissue oxygenation during hemorrhagic shock and resuscitation. Microvasc Res 1997; 54:164-173
20. Gradl G, Gaida S, Gierer P, et al: In vivo evidence for apoptosis, but not inflammation in the hind limb muscle of neuropathic rats. Pain 2004; 112:121-130
21. Gradl G, Gaida S, Finke B, et al: Exaggeration of tissue trauma induces signs and symptoms of acute CRPS I, however displays distinct differences to experimental CRPS II. Neurosci Lett 2006; 402:267-272
22. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
23. Mizutani A, Okajima K, Uchiba M, et al: Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95:3781-3787
24. Yamaguchi Y, Hisama N, Okajima K, et al: Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver. Hepatology 1997; 25:1136-1140
25. Macias WL, Yan SB, Williams MD, et al: New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005; 9:S38-S45
26. Sturn DH, Kaneider NC, Feistritzer C, et al: Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102:1499-1505
27. Mosnier LO, Griffin JH: Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci 2006; 11:2381-2399
28. Bilbault P, Lavaux T, Launoy A, et al: Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: A cohort study in septic shock patients. Crit Care Med 2007; 35:69-75
29. Monnet X, Lamia B, Anguel N, et al: Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 2005; 31:1573-1576
30. Roback MG, Stack AM, Thompson C, et al: Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock 1998; 9:138-142
31. Murakami K, Okajima K, Uchiba M, et al: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87:642-647